Original article by David Swan
The Australian – Page: 13 : 7-Jan-21
The Australian Information Industry Association has urged federal Health Minister Greg Hunt to appoint a representative from the technology industry to the working group tasked with the rollout of the COVID-19 vaccine. The AIIA believes a digital expert is needed on the group, as it is worried that the separate sourcing of ICT software and systems by state and territory governments risks a "disjointed approach" that could result in a less effective national vaccination program. Members of the AIIA include Telstra, Salesforce and Apple.
AUSTRALIAN INFORMATION INDUSTRY ASSOCIATION LIMITED, APPLE PTY LTD, TELSTRA CORPORATION LIMITED – ASX TLS
Original article by John Kehoe
The Australian Financial Review – Page: 5 : 6-Jan-21
Prime Minister Scott Morrison says he hopes lower numbers of COVID-19 cases in Sydney in recent days could see border restrictions between Victoria and New South Wales "eased as soon as possible". However, he has conceded he does not have the power to stop premiers and chief ministers closing their borders for health reasons. Morrison rejected criticisms that the federal government was taking too long to rollout a COVID-19 vaccine, saying that the Therapeutic Goods Administration needs to rigorously examine vaccine testing data, while vaccine batches in Australia will also need further testing.
AUSTRALIA. DEPT OF THE PRIME MINISTER AND CABINET
Original article by Sue Dunlevy
Herald Sun – Page: 13 : 16-Dec-20
The federal government will compile the list of people who will be given priority in receiving a COVID-19 vaccine when it releases expert advice on the roll-out strategy in late January. However, frontline health workers and aged-care staff will be the first to receive a vaccine. The government will also prioritise people based on age, with the nation’s population to be divided into 12 age brackets. People aged 70+ will receive a vaccine first, followed by those in the 65-70 age group. The rest of the population will be divided into five-year increment age groups. The UK has adopted a similar strategy for its COVID-19 vaccination program.
Original article by Jared Lynch
The Australian – Page: 15 : 8-Sep-20
Biopharmaceutical giant CSL has secured a $1.7bn deal with the federal government to produce 80 million doses of two coronavirus vaccine candidates. This comprises 30 million doses of the vaccine that is being developed by Oxford University and AstraZeneca, and 50 million doses of the vaccine that CSL is developing with the University of Queensland. Phase three clinical trials have commenced on the Oxford vaccine, while the home-grown vaccine is in phase one trials. The government will contribute $300m to the cost of upgrading CSL’s advanced manufacturing facility in Melbourne to produce the vaccines.
CSL LIMITED – ASX CSL, OXFORD UNIVERSITY, ASTRAZENECA PLC
Original article by Ben Potter
The Australian Financial Review – Page: 17 & 22 : 18-Aug-16
CSL has posted a 2015-16 net profit of $US1.24bn ($A1.6bn), which is 10 per cent lower than previously. The blood products and vaccines group’s sales rose by eight per cent to $US6.13bn. Earnings per share fell by eight per cent to $US2.69, but increased by seven per cent on a constant currency basis. CSL has forecast underlying net profit and EBITDA growth of 11 per cent and 14 per cent respectively in 2016-17. Its shares closed five per cent lower at $A110.84 on 17 August 2016.
CSL LIMITED – ASX CSL, SHIRE PHARMACEUTICALS GROUP PLC, NOVARTIS AG, CSL BEHRING, WILSONS ADVISORY AND STOCKBROKING LIMITED, SEQIRUS PTY LTD